|
1
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gladson CL, Prayson RA and Liu WM: The
pathobiology of glioma tumors. Annu Rev Pathol. 5:33–50. 2010.
View Article : Google Scholar :
|
|
3
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Auffinger B, Tobias AL, Han Y, Lee G, Guo
D, Dey M, Lesniak MS and Ahmed AU: Conversion of differentiated
cancer cells into cancer stem-like cells in a glioblastoma model
after primary chemotherapy. Cell Death Differ. 21:1119–1131. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hemmati HD, Nakano I, Lazareff JA,
Masterman-Smith M, Geschwind DH, Bronner-Fraser M and Kornblum HI:
Cancerous stem cells can arise from pediatric brain tumors. Proc
Natl Acad Sci USA. 100:15178–15183. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beier D, Hau P, Proescholdt M, Lohmeier A,
Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier
CP: CD133+ and CD133− glioblastoma-derived
cancer stem cells show differential growth characteristics and
molecular profiles. Cancer Res. 67:4010–4015. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bao S, Wu Q, Sathornsumetee S, Hao Y, Li
Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD and Rich JN: Stem
cell-like glioma cells promote tumor angiogenesis through vascular
endothelial growth factor. Cancer Res. 66:7843–7848. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dey M, Ulasov IV, Tyler MA, Sonabend AM
and Lesniak MS: Cancer stem cells: The final frontier for glioma
virotherapy. Stem Cell Rev. 7:119–129. 2011. View Article : Google Scholar :
|
|
12
|
Uno M, Oba-Shinjo SM, Silva R, Miura F,
Clara CA, Almeida JR, Malheiros SM, Bianco AM, Brandt R, Ribas GC,
et al: IDH1 mutations in a Brazilian series of glioblastoma.
Clinics (Sao Paulo). 66:163–165. 2011. View Article : Google Scholar
|
|
13
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ,
et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med.
360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yan W, Zhang W, You G, Bao Z, Wang Y, Liu
Y, Kang C, You Y, Wang L and Jiang T: Correlation of IDH1 mutation
with clinico-pathologic factors and prognosis in primary
glioblastoma: A report of 118 patients from China. PLoS One.
7:e303392012. View Article : Google Scholar
|
|
15
|
Parsons DW, Jones S, Zhang X, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et
al: An integrated genomic analysis of human glioblastoma
multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sonoda Y, Kumabe T, Nakamura T, Saito R,
Kanamori M, Yamashita Y, Suzuki H and Tominaga T: Analysis of IDH1
and IDH2 mutations in Japanese glioma patients. Cancer Sci.
100:1996–1998. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dang L, White DW, Gross S, Bennett BD,
Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et
al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim
SH, Ito S, Yang C, Wang P, Xiao MT, et al: Oncometabolite
2-hydroxyglutarate is a competitive inhibitor of
α-ketoglutarate-dependent dioxygenases. Cancer Cell. 19:17–30.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chitneni SK: IDH1 Mutations in Glioma:
Considerations for radiotracer development. SM Radiol J.
2:10092016.PubMed/NCBI
|
|
20
|
Cui D, Ren J, Shi J, Feng L, Wang K, Zeng
T, Jin Y and Gao L: R132H mutation in IDH1 gene reduces
proliferation, cell survival and invasion of human glioma by
downregulating Wnt/β-catenin signaling. Int J Biochem Cell Biol.
73:72–81. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reya T and Clevers H: Wnt signalling in
stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park JI, Venteicher AS, Hong JY, Choi J,
Jun S, Shkreli M, Chang W, Meng Z, Cheung P, Ji H, et al:
Telomerase modulates Wnt signalling by association with target gene
chromatin. Nature. 460:66–72. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He H, Niu CS and Li MW: Correlation
between glioblastoma stem-like cells and tumor vascularization.
Oncol Rep. 27:45–50. 2012.
|
|
24
|
Li Q, Qiao G, Ma J and Li Y:
Downregulation of VEGF expression attenuates malignant biological
behavior of C6 glioma stem cells. Int J Oncol. 44:1581–1588. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gurung PM, Veerakumarasivam A, Williamson
M, Counsell N, Douglas J, Tan WS, Feber A, Crabb SJ, Short SC,
Freeman A, et al: Loss of expression of the tumour suppressor gene
AIMP3 predicts survival following radiotherapy in muscle-invasive
bladder cancer. Int J Cancer. 136:709–720. 2015.
|
|
26
|
Dirks PB: Brain tumor stem cells: Bringing
order to the chaos of brain cancer. J Clin Oncol. 26:2916–2924.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Torres S, Lorente M, Rodríguez-Fornés F,
Hernández-Tiedra S, Salazar M, García-Taboada E, Barcia J, Guzmán M
and Velasco G: A combined preclinical therapy of cannabinoids and
temozolomide against glioma. Mol Cancer Ther. 10:90–103. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheema TA, Kanai R, Kim GW, Wakimoto H,
Passer B, Rabkin SD and Martuza RL: Enhanced antitumor efficacy of
low-dose Etoposide with oncolytic herpes simplex virus in human
glioblastoma stem cell xenografts. Clin Cancer Res. 17:7383–7393.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Costello JF, Berger MS, Huang HS and
Cavenee WK: Silencing of p16/CDKN2 expression in human gliomas by
methylation and chromatin condensation. Cancer Res. 56:2405–2410.
1996.PubMed/NCBI
|
|
30
|
Nobusawa S, Watanabe T, Kleihues P and
Ohgaki H: IDH1 mutations as molecular signature and predictive
factor of secondary glioblastomas. Clin Cancer Res. 15:6002–6007.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xie F, Tang JJ, Wang X, Liu YH and Mao Q:
Correlation between IDH1 mutation and prognosis in supratentorial
high-grade astrocytomas. Sichuan Da Xue Xue Bao Yi Xue Ban.
44:184–187. 1922013.In Chinese.
|
|
32
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
33
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shen G, Shen F, Shi Z, Liu W, Hu W, Zheng
X, Wen L and Yang X: Identification of cancer stem-like cells in
the C6 glioma cell line and the limitation of current
identification methods. In Vitro Cell Dev Biol Anim. 44:280–289.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou XD, Wang XY, Qu FJ, Zhong YH, Lu XD,
Zhao P, Wang DH, Huang QB, Zhang L and Li XG: Detection of cancer
stem cells from the C6 glioma cell line. J Int Med Res. 37:503–510.
2009. View Article : Google Scholar : PubMed/NCBI
|
